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Abstract
Lethal factor, the enzymatic moiety of anthrax lethal toxin (LeTx) is a protease that inactivates mitogen activated protein
kinase kinases (MEK or MKK). In vitro and in vivo studies demonstrate LeTx targets endothelial cells. However, the effects of
LeTx on endothelial cells are incompletely characterized. To gain insight into this process we used a developmental model
of vascularization in the murine retina. We hypothesized that application of LeTx would disrupt normal retinal
vascularization, specifically during the angiogenic phase of vascular development. By immunoblotting and immunoflu-
orescence microscopy we observed that MAPK activation occurs in a spatially and temporally regulated manner during
retinal vascular development. Intravitreal administration of LeTx caused an early delay (4 d post injection) in retinal vascular
development that was marked by reduced penetration of vessels into distal regions of the retina as well as failure of
sprouting vessels to form the deep and intermediate plexuses within the inner retina. In contrast, later stages (8 d post
injection) were characterized by the formation of abnormal vascular tufts that co-stained with phosphorylated MAPK in the
outer retinal region. We also observed a significant increase in the levels of secreted VEGF in the vitreous 4 d and 8 d after
LeTx injection. In contrast, the levels of over 50 cytokines other cytokines, including bFGF, EGF, MCP-1, and MMP-9,
remained unchanged. Finally, co-injection of VEGF-neutralizing antibodies significantly decreased LeTx-induced neovascular
growth. Our studies not only reveal that MAPK signaling plays a key role in retinal angiogenesis but also that perturbation of
MAPK signaling by LeTx can profoundly alter vascular morphogenesis.
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Introduction
Over a decade ago our laboratory used the National Cancer
Institute’s Antineoplastic Drug Screen of 60 human cancer cell
lines to identify novel inhibitors of the mitogen-activated protein
kinase (MAPK) signaling pathway. Our search showed that
anthrax lethal toxin (LeTx) had a similar activity profile on
cancer cell lines as the mitogen-activated protein kinase kinase
(MAPKK or MEK) inhibitor PD98059 [1]. LeTx, derived from an
exotoxin produced by the gram-positive bacterium Bacillus
anthracis, is a binary toxin consisting of the 83 kDa Protective
Antigen (PA) and 90 kDa Lethal Factor (LF). PA alone is non-
toxic, but serves to translocate LF to the cytosol via the endosomal
pathway (reviewed in [2]). LF was subsequently shown to be a zinc
metalloprotease that cleaves the amino termini of MEK 1 and 2
[1,3] as well as MKK 3, 4, 6, and 7 [4,5] and causes their
inactivation. This leads to inactivation of three MAPK pathways:
the extracellular signal-related kinase pathway (ERK), the p38
MAPK pathway (p38), and the c-Jun N-terminal kinase pathway
(JNK) [6,7]. The ERK pathway is preferentially activated by
growth factors, while the p38 and JNK pathways respond to
cellular stresses such as osmotic shock and inflammatory cytokines
(reviewed in [8]).
We have used LeTx in xenograft studies to test the requirement
for MKK signaling in tumor growth and angiogenesis in vitro and
in vivo [9,10,11]. In all cases, LeTx causes a dramatic reduction in
tumor volume that is preceded by an abrupt decrease in vascular
perfusion and accompanied by a decrease in tumor vasculariza-
tion. Although LeTx treatment does decrease the release of a
number of angio-proliferative factors, including basic fibroblast
growth factor (bFGF), IL-8, and VEGF from tumor cells [11] it
appears that the primary effects of LeTx are mediated by a non-
tumor compartment, likely endothelial cells [11,12,13]. However,
a more detailed understanding of the effects of LeTx on tumor
endothelial cells has not yet been achieved.
To overcome limitations inherent in analysis of neovascular-
ization in tumor models, and to gain further insight into the
mechanism of LeTx action on tumor endothelium, we examined
the effects of LeTx treatment on the growth of vascularization in
the murine retina. Retinal vasculature forms postnatally, in a well-
characterized and highly reproducible manner, providing a
unique, convenient system to evaluate contributions to vascular
formation and development. Since vascular growth develops
primarily in two dimensions, the retina provides a convenient
model to directly observe developmental angiogenesis, as well as a
useful model to monitor and quantify changes in vascular growth.
By analogy to the tumor model, we hypothesized that application of
LeTx would disrupt MAPK signaling and alter normal retinal
vascularization, specifically during the angiogenic phase of vascular
development. Consistent with this, injection of LeTx at a time when
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inhibition in branching morphogenesis of vasculature in the inner
plexus. However, this was followed shortly afterwards by extensive
focal neovascular growth into the outer retina that was driven by
elevated vitreal VEGF. These results indicate that MAPK signaling
plays a key role in retinal angiogenesis and that perturbation of MAPK
signaling by LeTx can profoundly alter vascular morphogenesis.
Results
Retinal vascularization during the first three weeks of
post-natal development
The mouse retina provides a highly regulated and reproducible
system for the study of vascular development. It is a useful model for
understanding normal as well as pathological angiogenesis, and has
been extensively used to study vascular remodeling and maturation
(reviewed in [14]). Retinal vessels are organized in two dimensions, and
are restricted to the inner layers of the retina. In rodents, the retina is
avascular at birth, and the vascular system consists of three planar
vascular plexuses that develop postnatally over the first 3 weeks of life
(Fig. 1). The superficial plexus forms during the first postnatal week,
and spreads radially from the optic nerve head towards the periphery
at the ganglion cell layer. The superficial vessels then branch and
sprout perpendicular to the primary vascular network into the hypoxic
inner layers of the retina along the outer edge of the inner nuclear layer
(INL) during the second postnatal week and the inner edge of the INL
over the third postnatal week. These sprouted vessels then anastomose
laterally to form the deep plexus (outer INL) and intermediate plexus
(inner INL) (reviewed in [15]).
MAPK activation occurs in a spatially and temporally
regulated manner during retinal vascular development
To determine whether MAPK signaling is active during retinal
vascularization we first performed immunoblots with antibodies
against MAPKs. We observed that the ERK1/2 MAPK pathway
is transiently active at birth (PN0) and then increases through the
first week, peaking around PN10 and remaining elevated through
PN21 (Fig. 2A). By contrast, the p38 and JNK MAPK pathways
are only modestly active early in retinal vascular development
(PN0-PN3) (Fig. 2A). These data indicate that the ERK pathway is
active during retinal vascular development, particularly during the
angiogenic phase of sprouting and growth into the inner plexus
regions (from PN7 through PN21).
To determine where active ERK is expressed during retinal
angiogenesis, we manually dissected retinas and examined them
by immunofluorescence, staining them with an antibody to
phosphorylated ERK. We observed that pERK staining was most
pronounced in sprouting vessels, beginning at PN7 (data not
shown), and especially at PN10 (Fig. 2B). These data indicate that
ERK is activated in angiogenic sprouting buds. Collectively these
data indicate that ERK pathway activation is spatially and
temporally regulated in a manner that is consistent with its
hypothesized role in endothelial morphogenesis during vascular
development of the retina. These results provide justification for
the use of this model to gain insight into the effects of LeTx on
endothelial cells.
Retinal endothelial cells are accessible to lethal toxin
treatment
PA mediated entry of LF into cells depends upon cell surface
expression of either of two anthrax toxin receptors, TEM8 or
CMG2 [16]. To determine whether retinal endothelial cells
(RECs) were susceptible to lethal toxin (LeTx) administration, we
first isolated and purified RECs from adult C57BL/6 mice and
performed cytotoxicity assay using PA and FP59, a cytotoxic
fusion protein consisting of the N-terminus of LF genetically fused
with the ADP-ribosylating domain of Pseudomonas exotoxin A [17].
We observed that RECs were as sensitive to FP59 cytotoxicity as
SK-MEL-28, a cell line known to be capable of PA-mediated
uptake of LF [18] (Fig. 3A). These data indicate that anthrax toxin
Figure 1. Postnatal development of retinal vasculature in the mouse. Eyes were enucleated at the indicated days postnatally (PN), fixed in
4% paraformaldehyde, and retinas dissected. Retinas were stained with GSA, and vasculature analyzed by epifluorescent microscopy (A) or confocal
microscopy (B). Confocal images were generated by z-axis projections.
doi:10.1371/journal.pone.0006956.g001
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and that PA is able to mediate uptake of LF into these cells. Next,
to determine whether RECs were sensitive to LeTx, we analyzed
cell viability following LeTx treatment in vitro, and found that,
compared to SK-MEL-28, RECs were relatively insensitive to
LeTx treatment, even after 72 hr incubation (Fig. 3B). To ensure
that LF was in fact targeting its substrate within RECs following
PA-mediated internalization, we performed immunoblots with
antibodies against MEK1 and ERK. We observed that 5 h
treatment of REC with LeTx cause amino terminal cleavage of
MEK1 and loss of ERK phosphorylation (Fig. 3C). These results
indicate that whereas LF enters REC in a PA-dependent fashion
and inactivates MAPK signaling, the effects of LeTx treatment are
not toxic to these cells.
Having determined that LF could enter RECs in vitro, we next
tested the ability of LeTx to target RECs in vivo. To do this we
injected PA and FP59 into the vitreous of the eyes of C57BL/6
mice during development (postnatal day 10– PN10) and following
the maturation of retinal vasculature (PN21). When retinas from
treated eyes were manually isolated and stained with isolectin GS-
IB4 from Griffonia simplicifolia (GSA) to identify endothelial cells, we
observed that retinas treated with FP59 showed vascular
destruction at both timepoints (Fig. 3D). These results confirm
that retinal vasculature can be targeted by LeTx following
intravitreal injection.
LeTx administration causes an early delay in retinal
vascular development
We have previously shown that LeTx treatment results in reduced
tumor growth in xenograft models, and that this disruption in tumor
growth was accompanied by extensive reduction in tumor vascular-
ization [9,10,11]. Since similar factors like hypoxia and VEGF drive
both tumor angiogenesis and retinal vascularization, we hypothesized
that LeTx would alter retinal vascular development, specifically during
the angiogenic growth into the inner plexus regions. To test this LeTx
was delivered by intravitreal injection to PN10 mice, a time at which
there is active angiogenic sprouting of retinal vasculature into the inner
retina, and retinas were collected for imaging four days later (Fig. 4).
Confocal analysis of GSA-stained retinal whole mounts revealed LeTx
caused reduced vascular growth to the inner plexus compared to
untreated eyes and eyes treated with PA plus E687C, an inactive form
of LF [19] (Fig. 4A). This delay was marked by reduced penetration of
vessels into distal regions of the retina (Fig. 4B) as well as failure of
sprouting vessels to form the deep and intermediate plexuses within the
inner retina (Fig. 4A and 4C).
LeTx administration causes a later retinal vascular
neovascularization
ToassessthelongtermeffectofLeTxtreatmentonretinalvascular
growth, we imaged retinas 8 days following LeTx treatment (Fig. 5).
Fluorescent microscopy revealed the presence of neovascular-like
growth throughout the retina following LeTx treatment compared to
the control treatment (Fig. 5A and 5B, left). To determine whether
these neovascular tufts were located within the inner retina, where
LeTx treatment had induced an earlier delay in vascular growth, we
imaged retinas by confocal microscopy. We observed neovascular
growth into and through the inner retina into the outer retinal region
(Fig. 5C and 5D, and Figure S1). The extent of growth through the
retinal layers was significantly increased following LeTx treatment
compared to control treatment (Fig. 5B, right). These data indicate
LeTx treatment causes highly abnormal retinal neovascularization 8
days following injection.
MAPK activity is increased following LeTx treatment and
colocalizes to neovascular tufts
Based on our observations of MAPK in tumors and early retina,
we hypothesized that the ERK pathway would be active in LeTx-
Figure 2. MAPK is active and spatially expressed in developing retinal vasculature. (A) Western blot analysis of MAPK pathway activity
during retinal vascular development. Eyes were collected and retinal lysates were prepared from C57BL/6 mice at the postnatal (PN) days indicated.
Lysates from untreated (No UV) or UV-treated (UV) SK-MEL-28 cells were used as a positive control for MAPK activation. Immunoblotting shows
strong expression of phosphorylated ERK (pERK), especially during times of angiogenic vascular growth in the retina, while phosphorylated p38
(pp38) and JNK (pJNK) are weakly expressed at earlier timepoints. (B) Epifluorescent images at low (206) and high (606) magnification of PN10
retinas stained with GSA (red) and pERK (green), to indicate pERK staining specific to the sprouting vessels.
doi:10.1371/journal.pone.0006956.g002
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cence of active ERK 4 days following LeTx treatment showed
increased staining in the superficial layer of the retinal vasculature,
but not in the deeper plexus regions (Fig. 6A and 6B). In contrast,
retinas examined 8 days following LeTx treatment showed
increased active ERK staining not only in the superficial layer
(Fig. 7A) but also in the neovascular growths located throughout
the inner and outer retinal regions (Fig. 7B, inset). In both
instances, active ERK staining in the superficial layers appear to
be non-endothelial (Figs. 2B and 6A).
To test whether the effects of LeTx are mediated solely by MEK
1/2 inhibition, we injected the MEK1/2-specific inhibitor CI-
1040 (PD184352) into the vitreous and examined the retinal
vasculature 4 and 8 days later. Vitreal injections of CI-1040 did
not mimic the changes in retinal vascularization we observed
following LeTx treatment (Figures S2 and S3). These results
indicate that while the ERK pathway appears to be important in
retinal angiogenesis, it may not be the sole MAPK pathway
responsible for the effects from LeTx.
LeTx-mediated delays in vascular development trigger
increased vitreal VEGF that induce neovascular growth
The observed transient inhibition of retinal vascular develop-
ment followed by neovascularization that is caused by LeTx may
be explained if the initial decrease in retinal vasculature in the
inner plexus creates a hypoxic environment, causing elevated
VEGF signaling that in turn triggers neovascularization. To test
this we measured the level of soluble VEGF and other cytokines in
the vitreous of eyes 1 and 4 days following LeTx treatment. We
observed a significant increase in the levels of secreted VEGF into
the vitreous at both timepoints compared to sham injected eyes
(Table 1). In contrast, the levels of over 50 other cytokines,
Figure 3. Sensitivity of retinal endothelial cells by FP59 and LeTx in vitro and in vivo. (A, B) To assess the sensitivity of retinal endothelial
cells (REC) to FP59 or LeTx in vitro, REC (e) or SK-MEL-28 (m) were treated with (A)P A( 1mg/mL) and FP59 (10 ng/mL to 10,000 ng/mL), or (B)P A
(1 mg/mL) and LF (10 ng/mL to 10,000 ng/mL). Cell viability was assayed after 24 hr (A)o r7 2h r( B) and plotted as percent viability. Error bars
indicate standard deviation from three separate experiments, where each experiment was performed in triplicate. (C) Western blot analysis of MEK1
cleavage and MAPK inactivation following LeTx treatment of REC in vitro. REC were either not treated (NT), or treated with PA alone (PA; 1 mg/mL),
PA+E687C, an inactive form of LF (EC; 1 mg/mL and 100 ng/mL respectively), or LeTx (LT; 1 mg/mL PA and 100 ng/mL LF). Cells were treated for 5 hr
or 24 hr and lysates prepared for separation on SDS-PAGE. Immunoblots indicate cleavage of MEK1 following LeTx treatment via loss of N-terminal
epitope (MEK1 NT), as well as a decrease in phosphorylated ERK (pERK). (D) In vivo analysis of retinal vasculature following intravitreal injection of
FP59 and PA (0.02 mg FP59 and 0.1 mgP Ai n1mL) of postnatal day 10 (PN10) and PN21 C57BL/6 mice. Retinas were stained 18 hr after treatment with
GSA and flatmounted to compare vasculature between untreated and treated eyes. High magnification epifluorescent images show destruction of
retinal vasculature following FP59 treatment.
doi:10.1371/journal.pone.0006956.g003
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changed following LeTx treatment (Tables S1 and S2, and data
not shown). These data indicate that increased VEGF is an early
response to inhibition of vascularization caused by LeTx
treatment.
To test whether increases in vitreal VEGF induce neovascular
growth we coinjected LeTx with a VEGF neutralizing antibody
(VEGF-NA) at both a low dose (16) and high dose (106) at PN10
and analyzed retinas 4 and 8 days following treatment (Fig. 8 and
data not shown). We did not observe significant changes in
vascular growth to the inner retina 4 days following LeTx plus
VEGF-NA treatment (data not shown). However, coinjection of
VEGF-NA resulted in a significant decrease in neovascular
growth, particularly at the high dose (Fig. 8A and 8C). Using
confocal microscopy we observed a striking decrease in the extent
of neovascular growth into and through the inner retina following
addition of VEGF-NA compared to LeTx treatment alone
(Fig. 8B). These data indicate the development of neovascular
growth following LeTx treatment is VEGF-dependent, and
implicate the MAPK signaling pathways as important contributors
to retinal vascular growth and development.
Discussion
In this report, we have shown that LeTx can perturb
developmental vascular growth in a murine model of retinal
angiogenesis. LeTx treatment results in a transient delay in the
formation of the inner plexus layers of retinal vasculature. This is
accompanied by an elevation in the concentration of vitreal VEGF
that subsequently drives extensive neovascular growth through the
inner retina to the outer retinal region. To explain these observations
we propose that LeTx acts directly on endothelial cells to prevent
growth and remodeling of angiogenic sprouts as they extend into
distal region of the retina. While it is possible that the immediate
effects of LeTx are on another cell type that guides retinal
angiogenesis, such as glial cells, Alfano et. al. [13] have observed
that LeTx can directly inhibit endothelial motility and morphogenesis
in vitro. By perturbing formation of the inner plexus, LeTx should
Figure 4. LeTx treatment delays growth of retinal vasculature into the inner plexus. Mice at PN10 were intravitreally injected either with no
treatment (No Tx), E687C/PA (0.02 mg E687C and 0.1 mgP Ai n1mL) or LeTx (0.02 mg LF and 0.1 mgP Ai n1mL). Eyes were collected 4 days post
treatment, stained with GSA and flat mounted for confocal microscopy. (A) z-axis projection of GSA stained retinas show loss of inner plexus growth
followingLeTxtreatment.Thethreelayersofradialvascular growthareindicatedbycolorbarstotherightoftheimages,whichcorrespondtothedepth
codingimagesin(C).Whilethesuperficiallayer(green;adepthofapproximately30 mmfromthetopofthestack)ismaintainedinalltreatments,thereis
a lack of intermediate plexus (yellow; a depth of 45 mm) and deep plexus (red; a depth of 55–60 mm) growth in the LeTx treated retina (A and C). (B)
Depth of vascular growth from the superficial layer (green in A and C) through the deep plexus (red in A and C) was quantified from analysis of z-stack
sections. Error bars indicate standard deviation from a minimum of three separate experiments. * p,0.05 compared to E687C/PA treatment.
doi:10.1371/journal.pone.0006956.g004
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increases in VEGF that promote the formation of abnormal vascular
tufts later in development. The alternative explanation that LeTx
directly induces increases in VEGF seems unlikely since 1) in tumor
cells we have observed that release of VEGF and other cytokines is
suppressed by LeTx [10,11], and 2) in vitro studies show that MAPK
activity positively regulates VEGF release [20,21,22]. Thus increases
in VEGF associated with LeTx treatment are most likely a secondary
consequence of delayed formation of the inner plexus layers of retinal
vasculature. These results reveal important insights into the roles of
MKK signaling in retinal and tumor vascular biology as well as the
pathology of anthrax.
MKK signaling in retinal vascularization
The retinal vasculature is an accessible and well characterized
vascular system to study the development of blood vessels as the
vasculature is restricted to two dimensions and can be visualized in
vivo. Oxygen levels are the primary regulator of blood vessel
growth in the retina, and VEGF is a critical factor in endothelial
cell growth, survival, and permeability, both during normal
vascular development and during disease [15,23]. Formation of
the three plexus layers is controlled by precise guidance cues
involving both growth factor expression (most notably the
opposing actions of VEGF and PEDF) and cell-cell adhesion
mechanisms (such as R-cadherin) [24]. Astrocytes provide these
cues to guide growth of the superficial network, while Mu ¨ller cells
and extracellular matrix components regulate the confinement of
the deep plexus layers to the inner retina [25,26,27]. Thus, it was
remarkable that LeTx caused neovascularization in the outer
retinal layers. Similar patterns of deep neovascular growth were
observed when Tobe et. al. engineered mice that express VEGF in
photoreceptor cells [28]. Also, injection of R-cadherin specific
antibodies into the developing eye inhibits endothelial collater-
alization with astrocytes and causes vessels to migrate past the
deep plexus region and into the outer retina [26]. This indicates
either that LeTx disabled normal guidance cues in the inner retina
Figure 5. Neovascular tuft formation following LeTx treatment. Mice at PN10 were intravitreally injected either with E687C/PA (0.02 mg
E687C and 0.1 mgP Ai n1mL) or LeTx (0.02 mg LF and 0.1 mgP Ai n1mL). Eyes were collected 8 days post treatment, stained with GSA and flat
mounted for microscopic analysis. (A) Epifluorescent images of retinal wholemounts of either E687C/PA treated (top) or LeTx treated (bottom)
retinas. (B) The number of neovascular tufts between the two treatments was quantified and plotted as # tufts/pixel
2 (left), and depth of vascular
growth was quantified to indicate neovascular growth through the inner retina and into the outer retina (right). The number of neovascular tufts was
quantified using Imagine_0.16 software. Depth of growth of vasculature from the superficial layer through the deep plexus (for E687C/PA treatment)
or through neovascular growth (for LeTx treatment) was quantified from analysis of z-stack sections. Error bars indicate standard deviation from a
minimum of three separate experiments. * p,0.05 compared to E687C/PA treatment. (C) z-axis projection of GSA stained retinas show neovascular
growth through the inner retina and into the outer retina following LeTx treatment. The four layers of radial vascular growth are indicated by color
bars to the right of the images, which correspond to the depth coding images in (D).
doi:10.1371/journal.pone.0006956.g005
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stimulatory signal into the outer retinal layers. In either case, it is
apparent that MKK signaling plays an important role in
regulation of guidance cues that control the formation of the
vascular network in the retina.
Our observation that active ERK was localized to angiogenic buds
and neovascular outgrowths indicates that altered MKK signaling
also may be a factor in retinal neovascularization. In support of this,
increased ERK activity was detected in a rat model of ROP, and
intravitreous injection of ERK inhibitors reduced retinal neovascu-
larization in this in vivo model system [29]. Also, increased MAPK
activation has been reported in retinal ischemia-reperfusion models
[30,31], and recently, the JNK pathway has been shown to play a key
role in retinal neovascularization in a mouse model of retinopathy of
prematurity [32]. Collectively, these data argue that MAPK signaling
pathways could be a source of novel targets for therapeutic
intervention of ocular diseases that have an angiogenic component.
MKK signaling in tumor vascularization
Previously we observed that in mouse xenograft models LeTx
causes a dramatic reduction in tumor volume that is preceded by
an abrupt decrease in vascular perfusion and is accompanied by a
decrease in tumor vascularization [9,10,11]. However, it is not
clear how LeTx-mediated loss of MKK signaling affects vascular
function. Work in a zebrafish model of vascular function showed
that LeTx induces increases in vascular permeability without
causing cell death [33]. The experiments described in this paper
indicate that LeTx also can prevent vascular morphogenesis and
interfere with guidance systems that regulate vascular growth.
Several studies point to a rolefor MKK signaling in controlling the
releaseofVEGF and otherangioproliferativefactorsfromtumorcells
in vitro [20,34,35,36,37,38]. However, we and others have observed
that LeTx can inhibit growth and vascularization of tumors that are
deficient in toxin uptake [12,13]. These results indicate that the
primary target of LeTx is a non-tumor compartment. We do not yet
have conclusive evidence to indicate which compartment this is.
However, based on their ability to uptake and respond to LeTx,
endothelial cells are a good candidate. In support of this, Mavria et.
al. [39] have shown that the expression of dominant negative MEK1
in the vasculature of colorectal adenocarcinoma xenografts suppress-
es angiogenesis and tumor growth.
The role of LeTx in the pathology of anthrax
LeTx is considered the major virulence factor of anthrax and the
mediator of host lethality. Vascular pathologies such as hemorrhage
and septic shock are common features of anthrax and can be mimicked
by the injection of LeTx alone [40,41]. LeTx has been shown to alter
vascular permeability and endothelial cell function in clinical [42] and
Figure 6. Increased MAPK expression in the superficial layer following LeTx treatment. Retinas were isolated from mice treated on PN10
with either no treatment (NT), E687C/PA, or LeTx and collected 4 days later. Retinas were stained with GSA (red) and pERK (green), and flatmounted
for confocal microscopy. (A) y-axis projection and accompanying depth coding image, and (B) z-axis projection indicating both lack of growth of
intermediate (yellow in depth coding projection) and deep (red in depth coding projection) plexus vasculature following LeTx treatment, as well as
increased pERK staining in the superficial vasculature.
doi:10.1371/journal.pone.0006956.g006
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also alters vascular morphogenesis expands the pathogenic vascular
phenotype seen in anthrax disease. Based on the current results as well
as published studies it is reasonable to postulate that profound
endothelial dysfunction caused by systemic exposure to LeTx
contributes to the pathogenesis of this disease.
In summary, to gain insight into the effects of anthrax LeTx on
tumor blood vessels we turned to a mouse model of developmental
retinal vascularization. We hypothesized that application of LeTx
would disrupt MAPK signaling and alter normal retinal vasculariza-
tion, specifically during the angiogenic phase of vascular development.
Consistent with this, injection of LeTx at a time when active MAPK
could be found in angiogenic buds resulted in the inhibition in
branching morphogenesis of vasculature in the inner plexus. However,
this was followed shortly afterwards by extensive focal neovascular
growth into the outer retina that was driven by elevated vitreal VEGF.
These results indicate that MAPK signaling plays a key role in retinal
angiogenesis and that perturbation of MAPK signaling by LeTx can
profoundly alter vascular morphogenesis.
Materials and Methods
Ethics Statement
All experiments were done in compliance with the guiding
principles of the ‘‘Guide for the Care and Use of Laboratory
Animals.’’ Allprocedures wereapproved by the Van Andel Institute
(VAI) Institutional Animal Care and Use Committee (IACUC).
Cell Culture
Retinal endothelial cells (RECs) were isolated and cultured
essentially as described [46]. Briefly, eyes from 6 week old C57BL/6
littermates (a minimum of 6 pups) were enucleated, and retinas
dissected under sterile conditions in Hanks’ Buffered Salt Solution
(HBSS) containing 1X penicillin and streptomycin. Retinal tissue was
minced with a scalpel, and dissociated in serum-free DMEM
containing 1 mg/mL collagenase (Sigma, #C0130) for 1 hr at
65 rpm at 37uC. Cells were collected by centrifugation (2 x 400 g
for 10 min) and filtered through a 40 mm 50 mL conical insert filter
Table 1. Measurement of secreted VEGF into the vitreous
following LeTx treatment.
Treatment (Tx) 1 day post Tx 4 days post Tx
sham 107.7653.1 88.767.1
E687C/PA 135.0665.8 91.3612.1
LeTx 284.3661.4
* 124.3611.1
*
*p,0.01 compared to sham treatment. Differences between sham and E687C/
PA treatments were not statistically significant.
Measurements are in pg/mL; 6SD of three independent experiments.
doi:10.1371/journal.pone.0006956.t001
Figure 7. MAPK activation within neovascular tufts. Retinas were isolated from mice treated on PN10 with either no treatment (NT), E687C/PA,
or LeTx and collected 8 days later. Retinas were stained with GSA (red) and pERK (green), and flatmounted for confocal microscopy. (A) y-axis
projection and accompanying depth coding image, and (B) z-axis projection indicating neovascular growth (red in depth coding projection)
following LeTx treatment, as well as increased pERK staining in the superficial vasculature and in the neovascular tufts.
doi:10.1371/journal.pone.0006956.g007
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seeded onto fibronectin-coated (2 mg/mL) tissue culture plates in REC
media (DMEM containing 2 mM L-glutamine and 2 mM sodium
pyruvate, 20% fetal bovine serum, 20 mM HEPES, 1% non-essential
amino acids, 1% penicillin and streptomycin, 55 U/mL heparin
(Sigma, #H3149), and 100 mg/mL endothelial cell growth supple-
ment (Sigma, #E2759)). Upon confluence, cells were reseeded as
above and a portion was stained with FITC-conjugated CD31
antibody (BD Pharmingen, #558738) for verification of purity of the
culture. Cells were then used for subsequent experiments within three
passages. The human melanoma cell line, SK-MEL-28, was cultured
in RPMI-1640 (Invitrogen, #21870) supplemented with 5% fetal
bovine serum and 1% penicillin and streptomycin. All cells were
maintained at 37uCi nah u m i d i f i e d5 %C O 2 incubator.
Reagents
Protective antigen (PA), lethal factor (LF) and LF-E687C
(E687C), a mutant form of LF whereby a Glu to Cys substitution
at the zinc-binding site results in elimination of enzymatic activity
[1], were expressed in Bacillus anthracis (BH445) and purified
essentially as described [47,48]. Protein concentrations were
estimated using the bicinchoninic acid method and by densito-
metric analyses of Coomassie-Blue stained polyacrylamide gels.
FP59, a kind gift of S. Leppla, is a fusion protein of the PA-binding
domain of LF and the ADP-ribosylation domain of Pseudomonas
exotoxin A [49]. The MEK1/2 inhibitor CI-1040 (PD184352) was
purchased from US Biologicals (#P3120-55), diluted in DMSO at
a concentration of 100 mM, and further diluted in either water or
HBSS to a final working concentration of 100 nM. The VEGF
neutralizing antibody, VEGF-NA, (R&D Systems #AF-493-NA)
was prepared and stored as described by the manufacturer.
Cytotoxicity assays
In vitro cell viability assays were performed as described [48].
Cells were seeded in 96-well plates to 70% confluence. Cells were
then treated with fresh culture media containing a range of LeTx
concentrations (1 mg/mL PA+1–10,000 ng/mL LF in 10-fold
increments) or a similar range with PA and FP59. Cells were
Figure 8. LeTx-induced neovascular tuft formation is VEGF-dependent. Mice at PN10 were intravitreally injected either with E687C/PA
(0.02 mg E687C and 0.1 mgP Ai n1mL), LeTx (0.02 mg LF and 0.1 mgP Ai n1mL), or LeTx in conjunction with 16VEGF-neutralizing antibody (LeTx/1X;
15 pg/mL VEGFNA) or 106 VEGFNA (LeTx/10X; 150 pg/mL). Eyes were collected 8 days post treatment, stained with GSA and flat mounted for
microscopic analysis. (A) Epifluorescent images of retinal wholemounts of either E687C/PA treated, LeTx treated, or LeTx plus VEGFNA treated retinas
(LeTx/1X VEGFNA and LeTx/10X VEGFNA). (B) z-axis projection of GSA stained retinas show loss of neovascular growth following increasing addition
of VEGF-neutralizing antibody to LeTx treatment. (C) The number of neovascular tufts in retinal whole mounts for each treatment was quantified
using Imagine_0.16 software and plotted as # tufts/pixel
2. Error bars indicate standard deviation from a minimum of three separate experiments. *
p,0.02 compared to E687C/PA treatment. # p,0.03 compared to LeTx treatment.
doi:10.1371/journal.pone.0006956.g008
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was assayed using the CellTiter 96H Aqueous Non-Radioactive
Cell Proliferation Assay (Promega Corp.) according to the
manufacturer’s instructions.
Western blot analysis
Immunoblotting was performed essentially as described
[10,11,48]. For analysis of MEK cleavage by LeTx, RECs were
either untreated, treated with E687C/PA (100 ng/mL E687C,
1 mg/mL PA), or LeTx (100 ng/mL LF, 1 mg/mL PA) for 5 hr or
24 hr. To ensure activity of CI-1040, SK-MEL-28 cells were
treated with either 10% H2O or 10 nM CI-1040 for 24 hr. To
analyze the basal activity of the MAPK pathways during retinal
vascular development, eyes were collected from C57BL/6 mice
from postnatal day 0 to day 21, and retinas dissected. Retinal
tissue was homogenized in RIPA buffer (50 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM Na3VO4,
20 mM Na-pyrophosphate, 1% Triton X-100, 1% sodium
deoxycholate, and 0.1% SDS, with Complete EDTA-free Protease
Tablets (Roche Corp.)) with a micropestle. Cells or homogenized
tissue were then lysed in RIPA buffer, sonicated, and cleared by
centrifugation. Protein concentrations were determined using the
bicinchoninic acid protein assay (Pierce Biotechnology). Five mg
(for cell lysates) or 50 mg (for retinal lysates) were separated by
denaturing SDS-PAGE and transferred to PVDF membranes
(Millipore). Lysates of UV-treated SK-MEL-28 cells were used as a
positive control for pERK, pp38, and pJNK activation. Mem-
branes were immunostained with the following antibodies: MEK1
(N-terminal) 1:2000 (Upstate, #07–641), MEK1 (C-terminal)
1:200 (Santa Cruz #219), pERK 1:1000 (Cell Signaling,
#4377), ERK 1:1000 (Cell Signaling, #9102), pp38 1:1000 (Cell
Signaling, #4631), p38 1:1000 (Cell Signaling, #9212), pJNK
1:1000 (Cell Signaling, #9255), JNK 1:1000 (Cell Signaling,
#9258). Membranes were probed with appropriate horseradish
peroxidase-conjugated secondary antibodies at 1:2000 (KPL, Inc.).
Specific proteins were visualized by chemiluminescence (Lumi-
GLO Chemiluminescence Substrate, Cell Signaling), followed by
exposure to Kodak Biomax Light film (Eastman Kodak).
Immunoblots were stripped and reprobed with b-actin (1:2000;
Sigma, #A1978) for a loading control.
Animals and Intravitreal Injections
All experiments were done in compliance with the guiding
principles of the ‘‘Guide for the Care and Use of Laboratory
Animals.’’ All procedures were approved prior to use by the Van
Andel Institute (VAI) Institutional Animal Care and Use
Committee (IACUC). C57BL/6 mice were obtained from Jackson
Laboratories (Bar Harbor, ME) and the VAI breeding colony.
Mice were housed in the VAI animal facility with 12-hour light/
dark cycle and free access to food and water. C57BL/6 mice at
postnatal day 10 (PN10) were anesthetized by hypothermia as
described [50]. Briefly, mice were anesthetized by chilling in an ice
water bath approximately 5 min until they became immobilized.
Mice were placed on an ice pack to maintain anesthesia during the
procedure. Adult mice (PN21) were anesthetized by an intraper-
itoneal injection of Avertin (600 mL per 20 g body weight).
Intravitreal injections were performed as described [51]. For PN10
mice, the eyelids were separated using a Straight 15u Optimum
TM
Knife (BD Beaver), and eyes were proptosed with gentle pressure.
Intravitreal injections were performed under a dissecting scope
using a 32-gauge Hamilton needle and syringe to deliver 1 mLo f
treatment. For E687C/PA and LeTx treatments, one standard
dose (1SD) equals 10 mg of PA and 2 mg of LF or E687C in a
volume of 100 mL [11]. Therefore, 1SD for intravitreal injection at
1 mL volume corresponds to 0.1 mgP A +0.02 mg LF for LeTx and
0.1 mgP A +0.02 mg E687C for E687C. Similarly, an intravitreal
injection of 1SD of FP59/PA corresponds to 0.1 mgP A +0.02 mg
FP59. CI-1040 was used at a final concentration of 20 nM. The
dose of VEGF neutralizing antibody used was based on the ND50
value range of 0.05–0.15 mg/mL. Therefore, VEGF-NA was used
at a 16dose (15 pg/mL) and a 106dose (150 pg/mL), and was
used in conjunction with either 1SD LeTx or 1SD E687C/PA
(0.5 mL each for a final delivery volume of 1 mL). Following
treatment delivery, eyes were repositioned, lids were approximated
over the cornea as necessary, and a topical antibiotic (Neomycin
and Polymyxin B Sulfates and Dexamethasone Opthalmic
Ointment, Bausch&Lomb, Inc.) was applied.
Retinal whole mount preparation and
immunofluorescence
Eyes were enucleated 4 days or 8 days after intravitreal injection
and fixed in 4% paraformaldehyde for 2 hours on ice. Retinas
were dissected using standard procedures [26]. Briefly, eyes were
bisected equatorially at the limbus, the cornea and lens removed,
and the retina separated from the optic cup using a dissecting
microscope. Retinas were then postfixed an additional hour.
Retinas were soaked in 100% ice cold MeOH for 15 min, blocked
in 5% normal goat serum for 2 hr at room temperature, and then
incubated at 4uC overnight in Alexa594-conjugated Isolectin
Griffinia simplicificolia-IB4 (GSA; 1:200, Invitrogen #I21413) and
pERK (1:50, Cell Signaling #4377) in 0.3% TritonX-100 in PBS.
For pERK, retinas were further incubated with anti-rabbit
Oregon Green (1:400, Molecular Probes #06381) for one hour
at room temperature. In order to identify the various retinal cell
layers, retinas were incubated with 5 mg/mL DAPI (Invitrogen
#D1306). Retinas were radially relaxed and flat-mounted on glass
slides with Gel Mount Aqueous Media (Sigma #G0918).
Microscopic analysis
Epifluorescent images were acquired with a Nikon E600
microscope equipped with a Spot Insight QE camera. Identical
illumination and camera settings were used to obtain all images.
Optimization for color, brightness, and contrast was performed
using Adobe Photoshop CS2; all optimization was performed
identically for all images. For confocal microscopy, retinal whole
mounts were visualized using a Zeiss LSM 510 META confocal
microscope with Krypton-Argon (458, 477, 488, 514 nm), HeNe
(543 nm) and Ti-sapphire (800 nm) pulse lasers. Three dimen-
sional projections and depth coding images were produced from a
series of z-axis images made up of 1 mm slices. All images were
acquired and analyzed from peripheral regions of the retinal whole
mounts to avoid region-specific differences within the retina.
Vitreous collection and analysis for cytokine secretion
Vitreous fluid was collected as described [52] with some
modifications. Mice that were intravitreally injected with 1SD of
E687C/PA or LeTx, or sham injected, were euthanized and eyes
were collected 1 day or 4 days post injection (2 eyes per sample, 3
samples per treatment per timepoint). Eyes were rinsed in ice cold
Isolation Buffer (80 mM NaCl, 8 mM KCl, 2 mM EDTA pH 8.0,
50 mM Tris-Cl pH 7.2, Complete EDTA-free Protease Inhibitor
Cocktail (Roche; 1 tablet per 50 mL)). Eyes were then gently
homogenized in 250 mL Isolation Buffer using a micropestle.
Supernatant was collected by centrifugation at 12,000 x g for
30 min at 4uC, and snap frozen. Samples were sent to Rules Based
Medicine, Inc. (Austin, TX) for cytokine screening (Rodent MAP
v2.0).
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Neovascular tufts were quantified using Imagine_0.16 software
(developed in-house) and expressed as number of tufts per area as
measured in square pixels. Threshold intensity was set to a high
range to avoid false positives. A minimum of three retinas per
treatment per collection timepoint was analyzed. Depth of
vascular growth was calculated from analysis of immunofluores-
cently stained vasculature within confocal z-stack projections. Data
are presented as a mean6standard deviation. Data were analyzed
for significance by Student’s t-Test. A p value,0.05 was
considered significant.
Supporting Information
Figure S1 LeTx induces neovascular growth into the outer
retina. Retinas were isolated from mice treated on PN10 with
either E687C/PA (left) or LeTx (right) and collected 8 days later.
Retinas were stained with GSA (red) and DAPI (blue) and
flatmounted for confocal microscopy. Retinal cell layers are
indicated based on DAPI staining. Z-axis projections show that
neovascular growth occurs through the inner retina and continue
into the outer retina. GCL - ganglion cell layer; IPL - inner
plexiform layer; INL - inner nuclear layer; OPL - outer plexiform
layer; ONL - outer nuclear layer.
Found at: doi:10.1371/journal.pone.0006956.s001 (0.37 MB TIF)
Figure S2 Intravitreal injection of the MEK1/2 inhibitor CI-
1040 has no effect on retinal vascular growth. (A) Western blot
analysis indicating activity of CI-1040 in SK-MEL-28 cells in vitro.
SK-MEL-28 cells were either untreated (NT) or treated withvehicle
(H2O) or 10 nM CI-1040 for 24 hr. CI-1040 treatment resulted in
a loss of phosphorylated ERK (pERK) while having no effect on
total ERK levels (ERK). Untreated (2) or UV-treated (+) SK-MEL-
28 lysates were run as a positive control for pERK activation. (B)
Retinas were isolated from mice treated on PN10 with either HBSS
or 20 nM CI-1040, collected 4 days later, stained with GSA, and
flatmounted for confocal microscopy. Z-axis projections (top) and
depth coding images (bottom) indicate no effect of CI-1040
treatment on vascular growth into the inner plexus.
Found at: doi:10.1371/journal.pone.0006956.s002 (0.44 MB TIF)
Figure S3 Intravitreal injection of the MEK1/2 inhibitor CI-
1040 does not induce neovascular growth into the outer retina.
Retinas were isolated from mice treated on PN10 with either
HBSS or 20 nM CI-1040, collected 8 days later, stained with
GSA, and flatmounted for confocal microscopy. (A) Z-axis
projections (left) and depth coding images (right) show normal
vascular development to the inner plexus and no formation of
neovascular growth into the outer retina. (B) Epifluorescent images
at low magnification of flatmounted, GSA stained retinas show no
evidence of neovascular tuft formation 8 days after CI-1040
treatment by intravitreal injection.
Found at: doi:10.1371/journal.pone.0006956.s003 (0.59 MB TIF)
Table S1 Measurement of secreted cytokines into the vitreous 1
day post treatment.
Found at: doi:10.1371/journal.pone.0006956.s004 (0.36 MB
DOC)
Table S2 Measurement of secreted cytokines into the vitreous 4
days post treatment.
Found at: doi:10.1371/journal.pone.0006956.s005 (0.40 MB
DOC)
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